The 12 month follow up results should be available soon. If they’re as positive as the 3 month results indicated then along with the FDA early feasibility study approval it should put upward pressure on the shareprice.
It would be good however to source extra funding to ensure cashflow concerns don’t drag on the shareprice.
Ann: FDA Approves Early Feasibility Study for DurAVR THV System, page-19
Add to My Watchlist
What is My Watchlist?
